Following the lead of drug manufacturer Bohringer Ingelheim (BI), both AstraZeneca and GSK have announced that they will restrict the out-of-pocket (OOP) cost for all their inhaled drugs to $35 or less per month. AstraZeneca’s program, which begins on June 1, 2024, includes Bevespi Aerosphere Inhalation Aerosol, Breztri Aerosphere, Symbicort, and others. In addition, AstraZeneca substantially reduced the list price of Symbicort on January 1, 2024. GSK’s program, which will begin no later than January 1, 2025, includes Advair Diskus/HFA, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta, Trelegy Ellipta, Ventolin HFA, and others. GSK recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%. These announcements from AstraZeneca and GSK follow an earlier announcement on March 7, 2024 from BI who stated it will cap the OOP costs at $35 per month for eligible patients for all the company’s inhaler products. This includes products such as Atrovent HFA, Combivent, Spiriva, Stiolto, and Striverdi.
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio (astrazeneca-us.com)
GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month | Boehringer Ingelheim (boehringer-ingelheim.com)
